Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Grundschober

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Chemical Communications (Cambridge, England)|July 6, 2018
High-yielding <sup>18</sup>F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivoRhiannon Beard, Nisha Singh, Christophe Grundschober, et al.
Npj Biological Timing and Sleep|June 3, 2026
Modelling the effect of V1a receptor antagonism and its potential therapeutic effect in circadian disordersMarcelo Boareto, Jorge Mendoza, Sebastian C Holst, et al.
The Journal of Biological Chemistry|June 19, 2002
Neurosecretion competence. A comprehensive gene expression program identified in PC12 cellsChristophe Grundschober, Maria Luisa Malosio, Laura Astolfi, et al.
Bioorganic & Medicinal Chemistry|April 1, 2018
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogsRhiannon Beard, Andy Stucki, Muriel Schmitt, et al.
Frontiers in Cellular Neuroscience|December 25, 2023
Selective oxytocin receptor activation prevents prefrontal circuit dysfunction and social behavioral alterations in response to chronic prefrontal cortex activation in male ratsPhilipp Janz, Frederic Knoflach, Konrad Bleicher, et al.
Psychopharmacology|June 2, 2010
Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded ratsSteffen Klein, Laurent B Nicolas, Cristina Lopez-Lopez, et al.
Journal of Medicinal Chemistry|February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approachHasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2011
Imaging trait anxiety in high anxiety F344 rats: Focus on the dorsomedial prefrontal cortexEric P Prinssen, Laurent B Nicolas, Steffen Klein, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Chemical Communications (Cambridge, England)|July 6, 2018
High-yielding <sup>18</sup>F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivoRhiannon Beard, Nisha Singh, Christophe Grundschober, et al.
Npj Biological Timing and Sleep|June 3, 2026
Modelling the effect of V1a receptor antagonism and its potential therapeutic effect in circadian disordersMarcelo Boareto, Jorge Mendoza, Sebastian C Holst, et al.
The Journal of Biological Chemistry|June 19, 2002
Neurosecretion competence. A comprehensive gene expression program identified in PC12 cellsChristophe Grundschober, Maria Luisa Malosio, Laura Astolfi, et al.
Bioorganic & Medicinal Chemistry|April 1, 2018
Building bridges for highly selective, potent and stable oxytocin and vasopressin analogsRhiannon Beard, Andy Stucki, Muriel Schmitt, et al.
Frontiers in Cellular Neuroscience|December 25, 2023
Selective oxytocin receptor activation prevents prefrontal circuit dysfunction and social behavioral alterations in response to chronic prefrontal cortex activation in male ratsPhilipp Janz, Frederic Knoflach, Konrad Bleicher, et al.
Psychopharmacology|June 2, 2010
Examining face and construct validity of a noninvasive model of panic disorder in Lister-hooded ratsSteffen Klein, Laurent B Nicolas, Cristina Lopez-Lopez, et al.
Journal of Medicinal Chemistry|February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approachHasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 14, 2011
Imaging trait anxiety in high anxiety F344 rats: Focus on the dorsomedial prefrontal cortexEric P Prinssen, Laurent B Nicolas, Steffen Klein, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Pageof 2